| CAS NO: | 91032-36-9 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 1879.7 |
| Cas No. | 91032-36-9 |
| Formula | C88H97Cl2N9O33 |
| Solubility | Soluble in ethanol;Soluble in methanol;Soluble in DMSO;Soluble in dimethyl formamide |
| Chemical Name | 34-O-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-22,31-dichloro-7-demethyl-64-O-demethyl-19-deoxy-56-O-[2-deoxy-2-[(1-oxodecyl)amino]-β-D-glucopyranosyl]-42-O-α-D-mannopyranosyl-ristomycin A aglycone |
| Canonical SMILES | CCCCCCCCC/C(O)=N/[C@]([C@@](OC1=C2C=C([C@](/N=C(O)\[C@](/N=C(O)/[C@@](/N=C(O)\[C@@](N)([H])C3=CC4=C(O)C=C3)([H])CC5=CC(Cl)=C(O2)C=C5)([H])C6=CC(O)=CC(O4)=C6)([H])/C(O)=N/[C@](/C(O)=N/7)([H])C8=CC(C9=C([C@@]%10([H])C(O)=O)C=C(O)C=C9O[C@]%11([H])[C@](O)([H] |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
Teicoplanin A2-3 is a major component of the teicoplanin complex [1-3].
Teicoplanins, lipoglycopeptide antibiotics, are glycopeptide antibiotics produced by A. teichomyceticus that are broadly effective against Gram-positive bacteria in vitro. Teicoplanins consist of five major components (A2-1, A2-2, A2-3, A2-4 and A2-5), one hydrolysis component (A3-1), and four minor components (RS-1, RS-2, RS-3, RS-4) [1]. Teicoplanins have been recently used for the treatment of multitudinous aerobic and anaerobic Gram-positive infections. Teicoplanins have been rapidly and extensively absorbed from the peritoneal cavity and muscle, but very poorly absorbed from the gastrointestinal tract [2]. Teicoplanin is highly bound in plasma to albumin and in tissues. Both renal and nonrenal mechanisms have been implicated in the elimination of the drug. For at least after one day administration, the concentrations of teicoplanin in serum and urine exceeded the MIC ranging from 0.02-2 μg/ml on many pathogenic organisms [3].
References:
[1] Bernareggi A, Borghi A, Borgonovi M, et al. Teicoplanin metabolism in humans[J]. Antimicrobial agents and chemotherapy, 1992, 36(8): 1744-1749.
[2] Rowland M. Clinical pharmacokinetics of teicoplanin[J]. Clinical pharmacokinetics, 1990, 18(3): 184-209.
[3] Traina G L, Bonati M. Pharmacokinetics of teicoplanin in man after intravenous administration[J]. Journal of Pharmacokinetics and Pharmacodynamics, 1984, 12(2): 119-128.
m.cnreagent.com